HOME >> BIOLOGY >> NEWS
Virginia Tech Biologists' Discoveries Could Help Target Cancer Treatment

(Blacksburg, June 18, 1998) -- Johnson & Johnson Corp. and the Janssen Research Foundation have awarded a team of Virginia Tech biologists an $84,000 grant to pursue new discoveries regarding the chemistry that initiates cell differentiation, the point in the development of a multicellular organism at which cells become specialized for particular functions.

Results of the research by biology professor Charles Rutherford, Reyna Favis, research assistant professor, and Ian McCaffery, research associate, has the potential to become the backbone of gene therapy for cancer. "Dr. Rutherford's research is on the brink of a very interesting discovery in cancer biology, to identify critical points in signal transduction where there is the possibility for therapeutic intervention," explained Richard Connors, principal scientist for oncology and endocrinology research with the Janssen Research Foundation.

Cancer cells multiply faster than normal cells, and continue to multiply, or proliferate. Whereas normal cells receive molecular information that stops cell proliferation and starts cell differentiation, in the cancer cell the signals are either not present or not received.

Those molecules that are involved in the transition point between proliferation and cell differentiation are of particular interest with respect to the formation of a cancer cell, Rutherford explains. By using Dictyostelium, a type of slime mold widely used as a model system in the study of cell differentiation because of its similarity to human cell function at this level, Rutherford's research group discovered that a protein called Replication Protein A (RPA) acts not only in cell proliferation, but also is a regulator of cell differentiation. Because most anticancer drugs inhibit cell division by interfering with either DNA synthesis or repair, RPA is a potential target for therapeutic intervention.

"Using deletion analysis and site-directed mutag
'"/>

Contact: Charles Rutherford
rutherfo@vt.edu
540-231-5349
Virginia Tech
19-Jun-1998


Page: 1 2 3

Related biology news :

1. Two Virginia Tech energy-related inventions win R&D 100 awards
2. Virginia Tech researchers to release findings on Smith River Project
3. Virginia Tech professor honored with DeLaval Award
4. Virginia Techs smelly corpse plant due to bloom Aug. 4
5. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
6. Virginia Center for Coal and Energy Research helps implement global climate change initiative
7. Cell cycle research earns biologist Virginias top scientist award
8. Virginia Tech-led group receives third five-year international biodiversity grant
9. Virginia Tech researcher receives $1.8 million to study Arabidopsis genome
10. Virginia Tech and North Carolina State University to run Forest Nutrition Research Cooperative
11. Virginia Bioinformatics Institute central to Regional Center of Excellence

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... ... 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host ... by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... solutions for biopharmaceutical R&D, today announced that it has entered into a ... multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to ...
(Date:6/23/2020)... KEYNES, England (PRWEB) , ... June 23, 2020 ... ... in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer ... response project to support testing operations in the fight against the COVID-19 pandemic ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... , ... July 09, 2020 ... ... company, announced today that Massachusetts Institute of Technology (MIT) has expanded the ... license allows PathSensors to move into the point-of-care diagnostic market, focusing initially ...
(Date:7/1/2020)... CHARLOTTE, N.C. (PRWEB) , ... June 29, 2020 ... ... has reported year to date growth of 40% in 2020, despite many obstacles ... medical technology, MedShift aims to increase revenue for its partnered medical practices and ...
(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... ... to advance photodynamic therapy for treating cancer, today announced the company has entered ... (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., ... presented June 22-24 during the American Association for Cancer Research Virtual meeting. One ... the potent, consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
Breaking Biology Technology:
Cached News: